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SUMMARY 
Fertilized eggs of lower vertebrates contain substantial amounts of steroidal 
hormones such as estrogen transferred from mother during oogenesis.   
However, molecular roles for maternal estrogen in the early embryonic 
development are largely unknown. Here we show that maternal estrogen and 
estrogen receptor-α modulate retinoic acid (RA) metabolism and RA-responsive 
gene expression in medaka embryos. Treatments with excess estradiol, an 
anti-estrogen (tamoxifen), overexpression or knockdown of estrogen receptor-α 
(ERα) resulted in misregulation of RA-related gene expression such as raldh2 
(retinalaldehyde dehydrogenase), cyp26a1 (RA hydroxylase), fgf8 (fibroblast 
growth factor), rarα (RA receptor-α), and ahr1 (aryl hydrocarbon receptor). We 
propose that maternal estrogen/ERα plays a critical role in the feedback control 
of in vivo level of RA and that it also activates RA signaling for the development 
of hindbrain and vasculatures. This is the first report demonstrating that maternal 
estrogen supports successful embryonic development by controlling RA 
metabolism and signaling in early vertebrate embryos. 
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INTRODUCTION 
The early development of all animals must rely on maternal products such as 
RNA and protein that are loaded into the developing oocyte by the mother and 
present in the egg at the time of fertilization (Pelegri, 2003). These factors are 
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encoded by maternal-effect genes which enable the embryonic development 
including animal-vegetal polarity, egg activation, cleavage, body plan formation, 
and tissue morphogenesis during early and late embryonic stages and the 
transition from maternal to zygotic gene expression and translation (Abrams and 
Mullins, 2009; Li et al., 2010). In addition to the regulatory mRNA and protein, 
several types of cargo are loaded into oocytes. These include lipoprotein yolk, 
fat soluble vitamins A and E, retinoids, carotenoids, inorganic phosphate, iron, 
calcium, magnesium, and other minerals, thyroid hormones, cortisol, and sex 
hormones such as testosterone and estrogen (Lubzens et al., 2017). The bulk 
molecular cargo is used as a source of cellular energy and structural 
components for formation of embryos and larvae. Vitellogenin is the major yolk 
protein precursor, produced by the liver under regulation by estrogen in maturing 
females. Vitamin A (retinol), retinoids, and carotenoids are maternal sources of 
retinoic acid (RA) de novo synthesized in the embryos. RA is a well-known 
morphogen that binds to nuclear receptors for transcription and is essential for 
many aspects of animal development (Duester, 2008; Maden, 2002; Theodosiou 
et al., 2010). Maternally derived thyroid hormones and cortisol are deposited in 
fish egg yolk and accelerate larval organ system differentiation until larvae 
become capable of endogenous endocrine function (Brown et al., 2014). 
Absence of maternal thyroid hormones did not affect early specification of the 
neural epithelia but profoundly modified later dorsal specification of the brain and 
spinal cord as well as specific neuron differentiation (Camphino et al., 2014). 
Estrogen is synthesized in eumetazoan animals from cnidarians (Tarrant, 
2005) to vertebrates, and its nuclear receptor acts as a transcriptional regulator 
in bilaterians (Bertrand et al., 2011; Keay & Thornton, 2009). Estrogen receptor 
(ER) is widely expressed in different tissue types and is important in vertebrate 
endocrine systems such as sexual maturation, gestation, and oogonial 
proliferation and primary growth (Senthilkumaran et al., 2004). Eggs of 
vertebrate oviparous species such as birds (Groothuis et al., 2005), reptiles (Elf, 
2003), amphibians (Fortune, 1983), and fish (Iwamatsu et al., 2005) contain 
substantial amounts of steroidal hormones such as androgen and estrogen. 
These steroids are synthesized in the ovary by steroidogenic cells 
(Senthilkumaran et al., 2004) and are lipophilic, thus, probably deposited in the 
egg yolk during oogenesis. Fully grown oocytes of medakafish also contain 
substantial amounts of 17β-estradiol (E2) equivalent to the level in the fluid of 
the ovarian cavity (Iwamatsu et al., 2005). Although the concentration of E2 
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declines from the initial level to one-fourth after ovulation, fertilized eggs at 
one-day post-fertilization (dpf) contain half of the E2 level at fertilization, with the 
level further decreasing to a basal level by 2 dpf (Iwamatsu et al., 2005) when 
medaka embryos have organized most of fundamental body architectures 
(Iwamatsu, 2004). Similar kinetics of the developmental change in yolk steroids 
have been reported in teleost fish (Paitz et al., 2015) and reptiles (Elf, 2003; 
Paitz & Bowden, 2009). Recently, there has been increasing interest in the 
possibility that steroidal hormones deposited in the egg may comprise a major 
pathway by which mothers influence the embryonic development of their 
offspring (Elf, 2003; Groothuis et al., 2005). Although exogenous application of 
gonadal steroids to eggs have been reported to influence a wide range of traits 
such as sex determination, behavior, growth, morphology, immune function, and 
survival, physiological significance of maternal steroids in early development 
remains largely unclear. 
We have searched for chemical reagents that induce vascular damages in 
medaka embryos. We have shown that excess estrogen inhibits vascular 
formation in wild-type embryos (Kawahara et al., 2000) and that 
ERα-overproducing transgenic embryos are hyper-sensitive to estrogen, 
indicating that activation of ERα causes the estrogen-induced vascular defects 
(Kawamura et al., 2002). We also reported that treatments with the following 
reagents inhibit the development of common cardinal veins (CCV) on the yolk: 
excess RA, RA synthesis inhibitor (diethylamino-benzaldehyde, DEAB), retinoid 
receptor antagonists, agonist (β-nephthoflavone and dioxin) and antagonist 
(α-nephthoflavone) for aryl hydrocarbon receptor (AHR) (Hayashida et al., 2004). 
AHR is a ligand-activated nuclear receptor conserved among vertebrates and 
commonly known for its role in the adaptive metabolism of xenobiotics and in the 
toxic events that follow exposure to dioxin (Carney et al., 2006; F.-Salguero et al., 
1996; Mimura et al., 1997). On the other hand, AHR is also required for normal 
mammalian development of liver, peripheral immune system, heart, ovary, and 
vascular system (McMillan & Bradfield, 2007). We reported in medaka embryos 
that RA is required for transcriptional activation of a gene (ahr1) for AHR 
(Hayashida et al, 2004; Kawamura & Yamashita, 2002) and that the 
RA-mediated transcriptional activation of ahr1 plays a key role in the 
development of yolk veins (Sada et al, 2019). These studies indicate that 
accurate regulation of retinoic acid (RA) level and signaling is crucial for normal 
development of blood vessels.  
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In this study, we made a new finding that PD98059, a potent and selective 
inhibitor of MAP kinase kinases, inhibits CCV formation. MAP kinase pathway is 
a major constituent in FGF (fibroblast growth factor) and VEGF (vascular 
endothelial growth factor) signaling. FGF signaling plays important roles in many 
aspects of early vertebrate development (Böttcher & Niehrs, 2005; Dorey & 
Amaya, 2010), and is known to activate expression of raldh2 encoding 
RA-synthesizing enzyme, retinaldehyde dehydrogenase in Xenopus (Shiotsugu 
et al., 2004). VEGF binds to and activates VEGF receptor in angioblasts, and 
stimulates their proliferation, migration, and survival during vasculogenesis (the 
formation of blood vessels from de novo generation of endothelial cells) and 
angiogenesis (the process of new blood vessel formation from the pre-existing 
vessels) (Apte et al., 2019; Olsson et al., 2006). We also found that cyclopamine, 
an antagonist of hedgehog pathway, inhibits formation of CCV and axial vessels. 
It has been reported in zebrafish that Sonic hedgehog expression in the 
notochord triggers expression of VEGF in the somites, high levels of which 
promote arterial cell fate in endothelial cells (Herbert et al. 2009; Lawson, 2002). 
Williams et al. (2010) also reported that shh signaling-deficient zebrafish 
embryos fail to form dorsal aorta. In avian and murine embryos, Sonic hedgehog 
promotes the assembly of angioblasts into vessel tubes (Byrd and Grabel, 2004; 
Kolesová et al. 2008; Moran et al. 2011; Vokes et al., 2004). In the myogenesis 
of zebrafish embryos, shh plays a crucial role for the expression of myoD 
together with fgf8 and RA (Hamade et al., 2006).        
To explore the significance of maternal estrogen in early development, we 
next investigated synergistic or suppressive effects among estrogen, estrogen 
antagonist (tamoxifen), RA, RA synthesis inhibitor (DEAB), and MAP kinase 
pathway inhibitor (PD98059), and also used knockdown of era1 (ERα) and fgf8 
(fibroblast growth factor). We conclude that maternal estrogen/ERα is important 
for feedback control of RA level by modulating expression of raldh2 
(retinaldehyde dehydrogenase), cyp26a1 (RA hydroxylase), and fgf8. The 
RA-induced feedback mechanism is crucial to successful embryonic 
development in zebrafish (D.-McAuliffea et al., 2004; White et al., 2007). We 
also propose that maternal estrogen/ERα in turn acts positively for 
transcriptional activation of RA-responsive genes such as anterior-posterior 
hindbrain patterning genes (Campo-Paysaa et al., 2008) and ahr1 that is 
essential for vascular formation (Sada et al., 2019).  
 
 5 
MATERIALS AND METHODS 
Fish, embryo, and exposure to reagent.  
We used the d-rR strain of medaka fish, Oryzias latipes (Kawahara and 
Yamashita, 2000). The fish were maintained at 25 – 26oC under artificial 
photo-period of 14L:10D, and fed by powdered Tetramin (Tetra). Fertilized eggs 
were collected before 10 hpf, rinsed and immersed in Yamamoto’s salt solution 
(Sada et al., 2019; Yamamoto, 1969). Embryos were treated with reagents 
starting from 10 hpf unless otherwise indicated, incubated at 25 – 26oC under 
shading with alminum foil, and inspected for vascular development under a 
dissecting microscope at 3 dpf as described (Hayashida et al., 2004) or 
processed for analysis of mRNA. All reagents were purchased from 
Sigma-Aldrich except for Ro41-5253 (kindly provided by E.-M. Gutknecht, F. 
Hoffmann-La Roche Ltd, Basel), PD98059 (Promega or CalBiochem), R115866 
(Lieven Meerpoel or Johnson & Johnson), and 4-oxo all-trans-RA (Tront 
Research Chemicals). Reagents were dissolved in dimethyl sulfoxide or ethanol, 
and stored at –80oC. Stock solutions were diluted over 1,000-fold with 
Yamamoto’s solution before use. The solvents were added to the mock-treated 
eggs as controls. Experiments were done at least 3 times in which unit samples 
contained more than 30 or approximately 50 eggs for observation of vascular 
development or extraction of total RNA, respectively. Percent embryos with 
vascular damages were presented as average ± SD. Statistical significance 
between values of control and experiment was assessed by Student’s t-test or 
chi-square test. 
 
DAPI staining. 
Embryos were fixed with 4% paraformaldehyde at 4℃ for 24 h, transferred into 
PBS, and dechorionated by forceps. The dechorionated embryos were rinsed 
twice with PBS, and stained for DNA with 4', 6-diamidino-2-phenylindole (DAPI) 
(0.5 μg/ml) for 5 min under shading with aluminum foil. After washing twice with 
PBS, the embryos were removed from the yolk and examined under 
fluorescence microscope.   
 
RT-PCR. 
Total RNA was extracted using NucleoSpin kit (Macherey-Nagel) after 
homogenization of embryos with pellet mixers. RT-PCR analysis was done using 
Ready-To-Go RT-PCR beads (GE Healthcare) or by two-step reactions, first 
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with reverse transcriptase (ReverTra Ace, Toyobo) using oligo-dT as a primer 
and then with DNA polymerase (Ex Taq, Takara). For specific detection of era1 
and antisense-era1 RNAs, reverse transcription was done with the following 
primers:  
era1, 5’-GTAGGAGGTCATAAAGAGGG-3’;  
antisense-era1, 5’-CTTCCGTGTGCTCAAACTCA-3’. 
PCR was done at least 5 times for each RNA sample at optimal and 
suboptimal cycle numbers with gene-specific primers as follows:  
era1 and antisense-era1,  
F 5’-CTTCCGTGTGCTCAAACTCA-3’,  
R 5’-GTAGGAGGTCATAAAGAGGG-3’.  
Annealing at 60oC for 30 sec, extension at 72oC for 1 min, 320-bp amplified DNA. 
Nested PCR for era1,  
F 5’-CTTCCGTGTGCTCAAACTCA-3’,  
R 5’-GAGGGACTTTGTTCTTGCAC-3’.  
Annealing at 60oC for 30 sec, extension at 72oC for 1 min, 305-bp amplified DNA. 
Choriogenin H,  
F 5’-CGCCATCTACTACTTTCCCG-3’,  
R 5’-AATTTTGACCCATGATGAAA-3’.  
Annealing at 61oC for 1.5 min, extension at 72oC for 1 min, 830-bp amplified 
DNA.  
Choriogenin L,  
F 5’-ACAATGATGAAGTTCACTGCG-3’,  
R 5’-CTGCTCCACTGACCTCCTTC-3’.  
Annealing at 61oC for 1.5 min, extension at 72oC for 1 min, 1050-bp amplified 
DNA. 
PCR primers for amplification of ahr1 and β-actin were described previously 
(Sada et al., 2019). After electrophoresis in agarose gel, amplified DNAs were 
stained with ethidium bromide and photographed. DNA bands were scanned 
with GT-9700F scanner (Epson), adjusted using software (Adobe Photoshop 
Elements 3.0), and analyzed for intensity with Scion Image software. Statistical 
significance was assessed by Student’s t-test. 
 
Whole-mount in situ hybridization.  
Whole-mount in situ hybridization was performed essentially as described 
(Inohaya, 1997). Embryos were treated with cycloheximide (50 or 100 mg/l) for 5 
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h before fixation in order to enhance ahr1, rarα (at gastrula stage), raldh2, and 
cyp26a1 mRNAs. If necessary, gastrula-stage embryos were fixed with 
paraformaldehyde in diluted (x 0.2 or x 0.4) Yamamoto’s solution or PBS in order 
to dissolve yolk material and avoid hybridization background. The resulting 
transparent embryos need to be handled with care. The cDNAs used as a 
template for preparation of probes were cloned in the following plasmids: ahr1 
(pOL97 or pOL100); cyp26a1 (pTM1); fgf3 (pKN5, provided by T. Czerny); fgf8 
(pKN6, provided by T. Czerny); hoxa3a (pOL145); krox20 (pOL150); myoD 
(pKN1); no tail (pKN3, provided by K. Araki); raldh2 (pOL155); rarα (pOL151); 
rarγ1 (pOL167); shh (pKN4, provided by K. Araki); sprouty4 (pKN2, provided by 
H. Takeda); and vegfr1 (pOL121 for sense, pOL122 for antisense). 
 
Introduction of plasmid DNA and morpholino into embryos.  
Plasmid DNA was introduced into one- to four-cell stage embryos by 
electroporation as described (Sada et al., 2019) or injected into 1-cell stage 
embryos as described (Yokoi et al., 2007). Plasmids pOL21 and pOL22 are used 
for expression of green fluorescent protein (GFP-S65T) and ERα (Kawamura et 
al., 2002), respectively. Plasmid pOL23 is used for expression of antisense-era1 
RNA from the entire sequence of the era1 cDNA (Kawahara et al., 2000). Every 
expression is driven by the medaka β-actin promoter (Hamada et al., 1998). 
Control morpholino (5’-CCTCTTACCTCAGTTACAATTTATA-3’) and fgf8-MO 
(5’-ATAGCTGCATGGCACGGGTCTCATC-3’) targeted to the 1st methionine of 
the medaka fgf8 gene were obtained from GeneTools (Corvallis, OR) and 
injected as described previously (Yokoi et al., 2007).  
 
RESULTS 
Search for chemical reagents that inhibit vascular formation. 
Previously, we reported that exogenously added 17β-estradiol (E2) but not 
17α-estradiol at 10 hpf causes blood aggregates at the blood island, loss of CCV, 
and edema under the head field at 3 dpf (Kawahara et al., 2000; Kawamura et 
al., 2002). To analyze when E2 is responsible for these vascular damages 
during the development, staged embryos were treated with E2 and examined at 
3 dpf. Half of the embryos became insensitive to E2 around 15 hpf (Fig. 1A), 
indicating that E2 affects vascular formation at an early gastrula stage 
(Iwamatsu, 2004). We also found that E2 causes curved tail at 6 dpf with the 
same sensitive period as that for vascular damages (Fig. 1A). 
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   To follow the development of CCVs, we visualized angioblasts by in situ 
hybridization using as a probe the medaka cDNA (vegfr1) (Hayashida et al., 
2004) encoding vascular endothelial growth factor receptor (VEGFR) (Fig. 1B). 
We observed that E2 inhibited CCV formation on the yolk at 48 hpf in wild-type 
embryos at high concentration (4 mg/l) but did not at concentrations less than 2 
mg/l (not shown). However, CCV did not form in ERα-overproducing transgenic 
embryos in the presence of an extremely lower concentration of E2 (1 μg/l), 
indicating that hyperactivation of ERα causes loss of CCV. Next, to investigate 
whether E2 affects the accumulation of angioblasts at the prospective brachial 
arch (PBA), the earliest known event essential for CCV formation (Sada et al., 
2019), we examined angioblasts at both 36 and 48 hpf. E2 did not affect an early 
appearance of angioblasts at PBA at 36 hpf, but inhibited further accumulation at 
48 hpf (Fig. 1C). These results indicate that E2/ERα damages CCV formation by 
inhibiting accumulation of angioblasts at PBA. 
   We also reported previously that excess RA causes vascular damages 
(Hayashida et al., 2004) and loss of CCV, however, does not inhibit the 
accumulation of angioblasts at PBA (Sada et al., 2019). We here examined the 
sensitive period to excess RA by treating staged embryos with 9 nM RA followed 
by in situ hybridization of 48-hpf embryos with the vegfr1 probe. The embryos to 
which RA was added at or before 25 hpf accumulated angioblasts at PBA but did 
not form CCV, while they became insensitive to RA around 30 hpf after entering 
into somite stage (Fig. 2A).     
   Although exogenously added RA inhibited CCV formation, it is uncertain 
whether the concentration of excess RA is physiologically relevant. To test this, 
we used R115866, a specific inhibitor of RA-metabolizing enzyme CYP26 
(Hernandez et al., 2007). This drug showed the same defective traits as 
exogenously added RA such as vascular damages including loss of CCV and 
malformation of head and body (Fig. 2B). These damages were recovered by 
co-treatment with the RA synthesis inhibitor DEAB (Fig. 2B). These results 
indicate that proper control of RA level is essential for early development of 
medaka embryos. 
   We newly examined the effect of the MAP kinase pathway inhibitor, PD98059. 
We investigated the effect of the drug beforehand by analyzing expression of 
sprouty4, a well-known downstream target of FGF signaling (Fürthauer et al., 
2001; Yokoi et al., 2007). As expected, the drug well inhibited sprouty4 
expression (Fig. 3A). We then examined the effect of the drug on vessel 
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formation. The drug caused vascular damages and inhibited CCV formation (Fig. 
3B). However, the treated embryos accumulated angioblasts at PBA as in the 
presence of excess RA (Fig. 3B). The drug also caused curved tails (Fig. 3C), 
the same developmental defect as that caused by the treatments with E2 (Fig. 
1A) and DEAB (Hayashida et al., 2004). In the time-lapse experiment, embryos 
became insensitive to the drug after entering into the somite stage (Fig. 3D), 
showing the same sensitive period as that for excess RA. 
   Finally, we tested whether cyclopamine is effective in medaka embryos. The 
drug caused vascular damages (Fig. 4A), loss of CCV (Fig. 4B), and curved tails 
(Fig. 4C), however, did not affect the accumulation of angioblasts at PBA (Fig. 
4D). These results suggest that shh signaling originating from notochord is 
important for angioblasts to form CCV on the surface of the yolk.  
Next we investigated whether E2 would affect myogenesis, because the 
curved tail caused by E2 is the same trait as observed in the treatments with 
DEAB (Hayashida et al., 2004), PD98059, and cyclopmaine. These drugs are 
expected to inhibit myoD expression because RA, fgf8, and shh are required for 
myoD expression in the zebrafish myogenesis (Hamade et al., 2006). We 
observed that myoD is expressed only in somites (Fig. 5A) as reported 
previously (Yokoi et al., 2007), while, in zebrafish, expressed in both somites 
and adaxial cells. As expected, RA was required for and activated myoD 
expression (Fig. 5A). PD98059 inhibited myoD expression (Fig. 5B) as expected 
that FGF signaling would be inhibited by the MAP kinase inhibitor. Unexpectedly, 
cyclopamine also inhibited somitic myoD expression (Fig. 5B), while in zebrafish 
shh is required for myoD expression in adaxial cells but not in somites. These 
results represent an additional example of the evolutionary difference in the 
regulation of myogenesis between medaka and zebrafish. As expected on the 
basis of defective traits in body axis, E2 inhibited myoD expression (Fig. 5C). 
Furthermore, co-treatment with E2 and DEAB showed a synergistic effect (Fig. 
5D), suggesting that the action of E2 is closely related to RA signaling. Another 
possibility is that E2 affects FGF or shh signaling. We then investigated whether 
E2 affects expressions of shh and no tail, markers for midline mesoderm or 
notochord. We observed no effect of E2 on the expression of shh during 25 to 48 
hpf (Fig. 6A) or of no tail during 19 to 48 hpf (Fig. 6B). We also observed no 
effects of PD98059 and DEAB on shh expression at 36 hpf (Fig. 6C). These 
results indicate that shh expression is not a target of these drugs.   
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Synergistic effects. 
To investigate whether E2 affects CCV formation in association with RA and FGF 
signaling, embryos were treated with every pair of E2, RA, DEAB (RA synthesis 
inhibitor), and PD98059 (MAP kinase pathway inhibitor). First, we examined the 
effect of co-treatment with E2 and DEAB at a low concentration that alone show 
minor effect, resulting in synergistic elevation of per cent embryos with vascular 
damages (Fig. 7A) including loss of CCV (not shown). These damages persisted 
during the gastrula stage well beyond the E2-effective blastula stage (Fig. 7B). 
These results suggest that E2 acts negatively on RA activity. We further 
examined whether E2 acts through binding to ERα. To test this, we used 
ERα-overproducing transgenic embryos (Kawamura et al., 2002). The embryos 
showed significant increase in vascular damages after treating with E2 and 
DEAB, either alone or together, at concentrations ineffective to wild-type 
embryos (Fig. 7C). Introduction into wild-type embryos of plasmid DNA 
expressing ERα under control of β-actin promoter also increased vascular 
damages in the presence of DEAB (Fig. 7D). These results indicate that 
hyperactivation of ERα is responsible to the vascular damages.      
   Next we investigated synergism between PD98059 and DEAB, resulting in 
gross elevation of vascular damages (Fig. 7E) including loss of CCV (Fig. 7F). 
Embryos became insensitive to the cotreatment after entering into late gastrula 
stage (Fig. 7G). The sensitive period was the same as that for the cotreatment of 
E2 and DEAB, well before the sensitive period for the treatment with PD98059 
alone. These results suggest that MAP Kinase acts positively both on RA activity 
(or signaling) at gastrula stage and for CCV formation at early somite stage. 
   We also examined the effect of co-treatment of E2 with PD98059, because 
each alone caused the same developmental defects such as vascular damages 
and curved tails, resulting in synergistic effects on both traits (Fig. 7H). This 
result is consistent with the notion that E2 inhibits MAP Kinase pathway. We also 
speculate that E2 and PD98059 synergistically inhibit RA activity, because both 
drugs increased the vascular damages in the presence of DEAB, as described 
above. We then examined whether both drugs would lower the inhibitory activity 
of ectopic RA. Contrary to our speculation, we observed that both drugs 
increased vascular damages synergistically with RA (Figs. 7I, K). Embryos 
co-treated with ineffective concentrations of RA and PD98059 lost CCV but 
accumulated angioblasts at PBA (Fig. 7J) like those treated alone with excess 
RA or PD98059. Embryos co-treated with RA and E2 also showed vascular 
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damages during the gastrula stage (Fig. 7L) like those treated alone with excess 
RA and PD98059. These results suggest that RA and E2 inhibit MAP kinase 
pathway.  
   Finally, we investigated the effect of co-treatment of E2 (2 mg/l) with 
cyclopamine (2 or 4 mg/l), resulting in no synergistic effect on vascular formation 
(data not shown), suggesting no functional link between E2 and cyclopamine. 
 
Effects of E2 on RA metabolism and signaling. 
We investigated whether E2 affects anterior-posterior patterning of hindbrain 
that is well known to be controlled by RA in chordate (Campo-Paysaa et al., 
2008). As expected for negative control of RA activity, E2-treated embryos 
showed wider rhombomeres than controls like DEAB-treated ones at 58 hpf (Fig. 
8A). Furthermore, we observed synergistic effect on rhombomere width of 
co-treatment of E2 with DEAB that alone showed no effect (Fig. 8B). E2 
(17β-estradiol) but not 17α-estradiol also caused moderate shift of rhombomere 
to posterior direction as evident from krox20 expression in rhombomere (r)-3 and 
r-5 (Fig. 9A). These results support our conclusion that E2 acts negatively on RA 
activity.     
   To verify this, we examined whether E2 affects RA-responsible gene 
expression such as rarα (inducible), raldh2 (repressible), and rarγ1 as a 
constitutive control (Sada et al., 2019) (Fig. 9A). The regulatory pattern of rarα 
and raldh2 by RA was evident from results of treatment with a RAR antagonist, 
Ro41-5253: posterior shift of r-3 and r-5; decrease in rarα expression; and 
increase in raldh2 expression. We observed that E2 inhibited rarα expression but 
showed no effect on rarγ1, suggesting that E2 represses rarα expression directly 
or indirectly by lowering RA level. Consistent with the latter possibility, E2 
repressed expression of raldh2 encoding RA-synthesizing enzyme. The 
E2-induced regulation was apparently caused by estrogenic activity of E2 
(17β-estradiol), because a chiral isomer, 17α-estradiol, showed no effect. We 
also observed synergistic inhibition with E2 and DEAB of rarα expression and of 
r-7 to r-8 expression of hoxa3a that is RA-inducible (Sada et al., 2019) (marked 
by open triangle) (Fig. 9B), confirming the inhibitory activity of E2 against RA 
activity.     
   To further clarify the suppressive effect of E2 against RA level, staged 
embryos were treated with E2 and examined at 36 hpf for rarα expression. 
Embryos to which E2 was added at or before 19 hpf showed reduced expression 
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in a slightly posterior region, while there was no effect of E2 after 20 hpf (Fig. 9C). 
Considering the previous observation (Sada et al., 2019) that expressions of 
rarα and raldh2 increase grossly after 19 hpf (about 60% epiboly), results of the 
time-lapse experiment suggest that loss of E2 inhibition would be due to 
increase in de novo synthesis of RA. Consistent with this, E2 was effective even 
at 20 hpf in the presence of minimum concentration of DEAB (Fig. 9B). 
Furthermore, addition of E2 at 10 hpf reduced expression levels of rarα in 18-hpf 
embryos in a concentration-dependent manner (Fig. 9D). Together, these results 
suggest that E2 inhibits RA synthesis.         
   Next we investigated whether E2 affects RA metabolism during the gastrula 
stage by analyzing expression of genes, raldh2 and cyp26a1, encoding RA 
synthesizing and metabolizing enzymes, respectively. To investigate the effect of 
E2 on raldh2 expression, embryos were first treated with E2 or mock-treated at 
10 hpf, to which cycloheximide (CHX) was added at 18 hpf to enhance 
hybridization signal, and fixed at 23 hpf. We observed that E2 reduced raldh2 
expression at the edge of the blastoderm (Fig. 10A) as observed at the somite 
stage (Fig. 9A). Next, to investigate whether this repression is direct or whether 
translation of intermediate signals is required, embryos were first treated with 
CHX at 17 hpf, to which E2 or mock solvent was added at 18 hpf, and fixed at 23 
hpf. As shown in Fig. 10B, E2 repressed raldh2 expression even in the presence 
of CHX, indicating a direct effect. We also investigated the effect of E2 on 
cyp26a1 expression. We observed that E2 increased cyp26a1 expression at 
presumptive anterior head (Fig. 10C), while did not in the presence of CHX (Fig. 
10D). Therefore, E2 appears to require translation of downstream factors to 
mediate its effect on cyp26a1. Together, these results suggest that addition of 
excess E2 lowers in vivo levels of RA by inhibiting raldh2 and activating cyp26a1, 
consistent with the observations that E2 caused posterior shift of the 
rhombomere and reduction in expression of RA-inducible genes such as rarα 
and hoxa3a.      
 
MAP kinase modulates RA metabolism and signaling. 
To investigate whether MAP kinase modulates RA signaling, embryos were 
treated with increasing concentrations of PD98059 (MEK inhibitor) and analyzed 
for expressions at 36 hpf of RA-controlled genes, rarα, hoxa3a, and krox20. The 
drug was ineffective at 2 and 5 μM, but inhibited rarα expression moderately at 
10 μM and to a greater extent at 20 μM (Fig. 11A). The highest concentration 
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caused posterior shift of krox20 signal and moderate reduction in hoxa3a 
expression at r7 to r8 (Fig. 11A). The drug inhibited rarα expression 
synergistically with DEAB (RA synthesis inhibitor) (Fig. 11B). The synergistic 
inhibition of rarα expression was evident at an early gastrula stage but reduced 
at late gastrula stage (Fig. 11C) as observed when vascular damage was 
examined (Fig. 7G). We also observed that expression of rarα was inhibited by 
PD98059 alone at a middle gastrula stage (Fig. 11D). These results support 
again that MAP Kinase acts positively on RA signaling at gastrula stage.          
Next we investigated whether PD98059 affects RA metabolism during the 
gastrula stage by analyzing expression of raldh2 and cyp26a1 after treatment 
with PD98059 from 10 hpf to 18 or 24 hpf. In the 18-hpf embryos, the drug 
inhibited raldh2 expression (Fig. 12A) while activated cyp26a1 expression with 
enlarged area of expression but no effect on density (Fig. 12B). We also 
observed in 24-hpf embryos that the drug expanded cyp26a1 expression at 
anterior head and caused delayed gastrulation at tail region (Fig. 12C), 
consistent with the previous notion that MAP kinases are involved in cell 
migration during gastrulation (Krens et al., 2008). Together, these results 
suggest that MAP kinase is required for in vivo levels of RA by activating raldh2 
and repressing cyp26a1.  
Treatment with PD98059 alone caused vascular damages during somite 
stage (Fig. 3D), while the drug was effective during gastrula stage in the 
co-treatment with DEAB (Fig. 7G). Previously, we reported that RA is required 
for CCV formation at gastrula stage by activating expression of ahr1 at PBA 
(Sada et al., 2019). Accordingly, we speculated that co-treatment of PD98059 
with DEAB caused loss of CCV through inhibition of ahr1 expression at PBA 
while PD98059 alone affected CCV formation through another pathway. To test 
this, ahr1 expression was investigated after treating embryos with PD98059 in 
the presence or absence of DEAB. As expected, PD98059 inhibited ahr1 
expression at PBA in the presence of DEAB (Fig. 13A) while alone had no effect 
(Fig. 13B), further supporting the significance of MAP kinase in the RA signaling.       
 
Effects of E2 on FGF expression. 
We first analyzed expression patterns of fgf3 and fgf8 during the somite stage 
when PD98059 causes loss of CCV (Fig. 14A). fgf3 was expressed at 
midbrain-hindbrain boundary (MHB) and r-4 throughout the somite stage. During 
late neurula to 2-somite stage, fgf8 was mostly expressed at r-2, r-4, and tail bud, 
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and faintly in adaxial mesoderm at the level of r-2 and r-4. At 4-somite stage and 
later, fgf8 was expressed at telencephalon, MHB, and tail bud. These results 
were essentially the same as those reported previously (Hochmann et al., 2007; 
Ishikawa et al., 2008). 
To investigate whether FGF plays a role in the regulatory pathway of CCV 
formation that is inhibited by ectopic E2, embryos were treated with E2 and 
analyzed for fgf3 and fgf8 expression (Fig. 14B). There was no effect of E2 on 
fgf3 expression except a slight posterior shift at 30 and 36 hpf. Expression level 
of fgf8 was not affected by E2 during 19 to 30 hpf, however, clearly diminished 
specifically in MHB at 36 hpf. To confirm the effect of E2 on fgf8 expression, we 
analyzed expression of sprouty4, a downstream target of fgf8, during 19 to 48 
hpf (Fig. 14C). We observed specific inhibition of sprouty4 at MHB and its 
posterior adaxial mesoderm (bracket) at 36 hpf. While this inhibition was 
recovered later at 48 hpf, we observed unexpectedly somitic expression of 
sprouty4 (bracket) in the control embryos and its inhibition by E2. Furthermore, 
we observed that sprouty4 expression at MHB and posteriorly neighboring 
adaxial mesoderm was inhibited by E2 in a concentration-dependent manner 
(Fig. 14D). To investigate whether the negative regulation is mediated by ERα, 
embryos were injected with plasmid DNA expressing ERα, and analyzed for 
expressions of fgf8 at 36 hpf and myoD at 44 hpf. Embryos overproducing ERα 
appeared shorter in body length and showed inhibition of fgf8 expression at 
MHB and of myoD expression in the somites (Fig. 15). Collectively, these results 
suggest a role for E2/ERα in the negative regulation of fgf8 and myoD. 
 
fgf8 is required for CCV formation independently of RA signaling. 
Considering that ectopic RA inhibits CCV formation synergistically with either 
PD98059 or E2, we assumed that excess RA would act through FGF signaling. 
To investigate this, staged embryos were treated with RA and analyzed for fgf8 
and sprouty4 expressions at 36 hpf (Fig. 16A). fgf8 expression was specifically 
inhibited at MHB in the 10-hpf embryos but not in later embryos. Expression of 
sprouty4 was also inhibited at MHB exclusively at 10 hpf, while its expression at 
adaxial mesoderm and tail bud was inhibited in 10- to 25-hpf and 10- to 20-hpf 
embryos, respectively (Figs. 16A, B). These results indicate that RA has three 
target sites with different sensitive period: MHB at 10 hpf, adaxial mesoderm 
during 10 to 25 hpf, and tail bud during 10 to 20 hpf. The first and second 
sensitive periods are the same as those for E2 (Fig. 1A) and RA (Figs. 2A, 16B), 
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respectively, against vascular damages (Hayashida et al., 2004). Collectively, 
these results suggest that both RA and E2 inhibit CCV formation by decreasing 
fgf8 expression at MHB and adaxial mesoderm.  
We also examined whether excess RA would affect specific expression of 
ahr1 at PBA that is important for accumulation of angioblasts at PBA before CCV 
formation (Sada et al., 2019). After addition of excess RA at 10 and 18 hpf, 
expression of ahr1 was increased throughout the anterior head of malformed 
embryos, in which there was a mass of ahr1 expression (gray triangle) at or near 
the otic vesicle (open triangle) (Fig. 17A). Malformation of head structure was 
evident from the shorter distance between top of head and otic vesicle (double 
arrowhead) (Figs. 17A, B). However, there was no effect on ahr1 expression 
including the expression at PBA (closed triangle) after addition of RA at 24 hpf 
that is the time within the second sensitive period (Fig. 17A). These results 
suggest that ahr1 is not involved at least quantitatively in vascular damages 
caused by excess RA.                  
   To verify the significance of fgf8 in CCV formation and in RA signaling and 
metabolism, embryos were injected with control-MO or fgf8-MO and analyzed by 
in situ hybridization. We first examined the effect of fgf8-MO on FGF signaling by 
analyzing sprouty4 expression, resulting in moderate or severe reduction in half 
population each (Fig. 18A). Both type of embryos showed severe malformation 
of posterior structure, consistent with the somite-less phenotype reported 
previously (Yokoi et al., 2007). These results suggest that most of the expression 
at telencephalon, MHB, adaxial mesoderm, and tail bud in the embryos injected 
with control-MO is under the control of fgf8. We next examined CCV formation 
by visualizing vegfr1+ angioblasts. Embryos injected with fgf8-MO showed loss 
of the CCV with complete structure developing upward to head region, however, 
there was accumulation of angioblasts at PBA and short vessels formed near the 
PBA (Fig. 18A), indicating a critical role of fgf8 in the extension of CCV from PBA 
to heart lying beneath the head. To investigate the importance of fgf8 in the RA 
signaling, expression of RA-inducible genes, rarα and ahr1, was analyzed. 
Expression of rarα was reduced in the morpholino-knockdown embryos at 18 
and 36 hpf (Fig. 18A), which was lost synergistically by co-treatment with DEAB 
(Fig. 18B). These results suggest a role of fgf8 in RA signaling. However, there 
was no change in ahr1 expression at PBA (Fig. 18A), suggesting that ahr1 is not 
involved in the morpholino-induced vascular damages. This is consistent with 
the observation that angioblasts accumulated at PBA in the knockdown embryos, 
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which is required for ahr1 function (Sada et al, 2019). Next, to investigate 
whether fgf8 controls RA metabolism, we analyzed expression of 
RA-synthesizing and -catabolizing genes, raldh2 and cyp26a1, respectively. In 
the morpholino-knockdown embryos, expression of raldh2 was reduced, while 
expression area of cyp26a1 was expanded with no change in density (Fig. 18A) 
as reported previously that FGF signaling is necessary and sufficient for the 
suppression of the anterior gene cyp26 during gastrulation in zebrafish (Kudoh 
et al, 2002). These results are the same as those in embryos treated with MAP 
kinase inhibitor PD98059 (Fig. 12), suggesting that fgf8 raises concentration of 
RA by activating synthesis and repressing catabolism.        
 
Maternal estrogen controls RA-responsive gene expression and vascular 
formation through binding to ERα. 
To analyze rhombomere formation, embryos were stained with DAPI and 
examined under fluorescent microscope. We observed that axial width of unit 
rhombomere was lengthened in DEAB-treated embryos while ectopic RA 
caused malformation of the brain with posteriorized hindbrain (Fig. 19A), 
consistent with the established notion that RA controls anterior-posterior (A-P) 
patterning of hindbrain. To investigate whether maternal estrogen is involved in 
the A-P patterning, embryos were co-treated with RA and an anti-estrogen, 
tamoxifen (TAM). The co-treated embryos formed normal size of rhombomere, 
however, again deformed like RA-treated ones by further addition of E2 that 
alone caused no effect (Fig. 19A). We further analyzed expression of krox20, a 
marker for r-3 and r-5, resulting in anterior shift by ectopic RA, which was 
recovered by co-treatment with TAM (Fig. 19B). These results indicate that 
maternal estrogen is required for posteriorizing activity of RA. 
   To investigate whether maternal estrogen plays a role in expression of 
RA-inducible genes, rarα and hoxa3a, embryos were treated with RA in the 
presence or absence of TAM. We observed that excess RA could not activate 
expression of rarα and hoxa3a at r-7 to r-8 in the presence of TAM (Fig. 19C), 
indicating a role for maternal estrogen in the RA-inducible activation. In the 
time-lapse experiment, embryos activated rarα expression as estimated by both 
intensity and area of expression when RA was added before 18 hpf while could 
not in the presence of TAM (Figs. 19D, E). The short head caused by excess RA 
was also recovered by co-treatment with TAM (Fig. 19F). These results suggest 
that TAM was effective at early gastrula stage. 
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   Next, we investigated whether TAM inhibits RA-activation of rarα expression 
in the gastrula-stage embryos. Because of low expression, we could not detect a 
specific signal for rarα expression in the gastrula-stage embryos according to the 
conventional method. To enhance signal intensity, embryos were first treated 
with CHX for 5 h before fixation. We also improved how to exclude background 
signal in the yolk by fixing embryos in the diluted saline buffer in order to dissolve 
yolk materials. In this way, we detected clear signal of rarα expression at dorsal 
edge of blastoderm in the embryos treated with CHX at 13 and 16 hpf and at 
midline of the embryonic shield treated with CHX at 19 hpf (50% epiboly) (Fig. 
20A). To test the significance of maternal estrogen, embryos were treated with 
RA in the presence or absence of TAM at 10 hpf, with CHX at 18 hpf, and fixed 
at 23 hpf. Excess RA activated rarα expression, while co-treatment with TAM 
counteracted the effect of RA (Fig. 20B). These results confirm a role for 
maternal estrogen in the control of RA-inducible gene expression at gastrula 
stage. We also investigated whether maternal estrogen would directly activate 
rarα expression. To test this, embryos were first treated with CHX at 14 or 18 hpf, 
then with RA in the presence or absence of TAM at 15 or 19 hpf, respectively. In 
this scheme, RA activated rarα expression both in the presence and absence of 
TAM (Fig. 20C). These results suggest that RA activates rarα expression directly 
and that maternal estrogen acts indirectly or serves as a specific stabilizer for 
rarα mRNA which is exchangeable with CHX.          
   To confirm the significance of maternal estrogen in RA control of ahr1 
expression at PBA, embryos were treated with RA in the presence or absence of 
TAM at 18 hpf, with CHX at 48 hpf, and fixed at 53 hpf. Expression of ahr1 at 
PBA was increased by RA concomitant with posteriorization of hindbrain 
(anterior shift of otic vesicle), while recovered to a control level by co-treatment 
with TAM (Fig. 21). Further addition of E2 again increased ahr1 expression 
which occurred concurrently with posteriorization of hindbrain (Fig. 21). These 
results indicate that maternal estrogen is also required for RA-activation of ahr1 
expression and confirm the role of maternal estrogen in the RA-induced 
posteriorization of hindbrain.  
   We further investigated whether maternal estrogen is involved in inhibition of 
FGF signaling by ectopic RA. We observed that expression of sprouty4 at MHB 
and adaxial mesoderm was recovered with TAM from the RA-induced inhibition 
in the 36-hpf embryos (Fig. 22A). In the time-lapse experiment, in which RA was 
added at 10 hpf with addition of TAM at the indicated time, fgf8 expression at 
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MHB was restored with TAM before 20 hpf (Fig. 22B). These results suggest that 
maternal estrogen controls fgf8 expression negatively in concert with RA at early 
gastrula stage.   
   Next we examined whether ectopic RA inhibits FGF signaling cooperatively 
with maternal estrogen in the gastrula-stage embryos. We first examined the 
effect of high RA concentration on fgf8 expression by adding 9 nM RA at 10 hpf 
(Fig. 22C). At blastula/gastrula stage (13 hpf), RA showed no inhibition of fgf8 
expression at dorsal margin of blastoderm. At a middle gastrula stage (19 hpf), 
fgf8 is strongly inhibited by RA in the dorsal marginal mesoderm fated to become 
the tailbud. At late gastrula stage (24 hpf), fgf8 expression in the presumptive 
tailbud was separated (marked by arrowhead) because of delay in cell 
movement and gastrulation as reported previously in Xenopus (Sive et al., 1990), 
while there was no effect in the anterior neural region. To investigate a role of 
maternal estrogen in the inhibition of fgf8 expression, embryos were treated with 
TAM in the presence of RA, resulting in recovery from the RA-induced defects 
(Fig. 22C). We also observed the same results when sprouty4 expression was 
examined (Fig. 22D), confirming that maternal estrogen controls fgf8 expression 
negatively in concert with RA at gastrula stage. We also investigated whether 
the negative control of maternal estrogen is mediated through ERα by analyzing 
fgf8 expression at 19 hpf in the ERα-KD embryos. We observed increased 
expression of fgf8 (Fig. 22E), indicating that maternal estrogen binds to ERα and 
represses fgf8.     
   We also investigated whether ectopic RA would directly inhibit fgf8 
expression. To test this, embryos were first treated with CHX at 16 hpf, then with 
RA at 17 hpf. In this scheme, RA did no inhibit fgf8 expression (Fig. 22F), 
indicating an indirect role of the inhibitory activity of RA. We also examined 
whether RA present in the normal development of embryos would repress fgf8 
expression. To test this, RA synthesis was inhibited by addition of DEAB, then 
fgf8 expression was analyzed. We observed no effect of the RA deficiency on 
the expression of fgf8 at 19 and 36 hpf (Fig. 22G), indicating that normal level of 
RA does not control fgf8. We further investigated whether increased 
concentration of endogenous RA would suppress fgf8 by incubating embryos in 
the presence of the CYP26 inhibitor (R115866). We observed that the drug 
inhibited fgf8 expression at 19 hpf (Fig. 22H). Considering the role of fgf8 both in 
activation of raldh2 and inhibition of cyp26a1 shown in Fig. 18A, the result 
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indicates an important role of fgf8 in the feedback control of in vivo RA 
concentration. 
   Next we investigated whether maternal estrogen is required for the effect of 
excess RA on vascular formation. We observed suppression of the RA-induced 
vascular damages by co-treatment with TAM, which was canceled by further 
addition of E2 (Fig. 23A). We also observed that the synergistic inhibition of 
vascular formation by RA and E2 was recovered by TAM (Fig. 23B). These 
results indicate that maternal estrogen is involved in the ectopic RA-induced 
inhibition of vascular formation. To investigate the sensitive period for TAM, 
embryos were incubated in the presence of RA starting from 10 hpf with 
time-lapse addition of TAM, and analyzed for vascular damages and body axis 
malformation such as dysgenesis of head and tail. As shown in Fig. 23C, TAM 
was effective before early gastrula stage, the same one for ectopic E2 (Fig. 1A).   
   Next, we investigated whether maternal estrogen is required for vascular 
formation. We found no discernible morphological defects in the embryos treated 
with TAM at concentrations up to 4 mg/l from 10 hpf to 6 dpf. However, we 
observed that TAM caused vascular damages including loss of CCV in the 
presence of low dose of DEAB that alone showed minor effect (Figs. 24A, B). 
The embryos with vascular damages were apparently normal in other aspects of 
developments, suggesting that vascular cells are most sensitive to these drugs. 
The synergistic inhibition was partially rescued by addition of low dose of either 
RA (Fig. 24C) or E2 (Fig. 24D). These results suggest that maternal estrogen 
plays a role cooperatively with RA in vascular formation. To investigate when 
maternal estrogen is required, staged embryos were co-treated with TAM and 
DEAB, and examined for vascular damages at 3 dpf or vegfr1+ angioblasts at 48 
hpf. We also investigated the sensitive period for TAM by incubating embryos in 
the presence of DEAB starting from 10 hpf with time-lapse addition of TAM 
(closed square). We observed that embryos passing through middle gastrula 
stage became insensitive to TAM (Figs. 24E, F), indicating that maternal 
estrogen is required for vascular formation including CCV before the middle 
gastrula stage. 
To elucidate a role for maternal estrogen in the RA pathway in which RA 
activates transcription of ahr1 that is essential for CCV formation (Sada et al., 
2019), we analyzed transcript level of ahr1 by RT-PCR method under the 
conditions where E2 and TAM interact with RA and DEAB to cause vascular 
damage synergistically or suppressively. We first observed that co-treatment 
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with low dose of RA and E2 that alone showed no effect activated ahr1 
expression synergistically (Fig. 25A). Conversely, activation of ahr1 by high 
concentration of RA was suppressed by co-treatment with TAM, which was 
recovered by further addition of E2 (Fig. 25B). We also observed that ahr1 
expression was inhibited synergistically by co-treatment with a low dose of 
DEAB and TAM (Fig. 25C), which was recovered by addition of RA (Fig. 25D). 
These results suggest that ahr1 expression is activated cooperatively by RA and 
maternal estrogen. Specific expression of ahr1 at PBA was also abolished 
synergistically by DEAB and TAM (Fig. 25E) whereas rarα expression was not 
(Fig. 25F), indicating that the vascular damages caused by co-treatment with 
DEAB and TAM are due to loss of ahr1 expression at PBA.   
We then explored whether the action of maternal estrogen is mediated 
through ERα. We first analyzed transcript levels of ERα-encoding era1 in RNA 
samples extracted previously from blastula to somite stage (Sada et al., 2019). 
era1 expression was essentially constant during the developmental period, and 
estimated to be very low because amplified signals were first detectable after the 
second amplification of the first PCR product (Fig. 26A), consistent with the 
previous observation that no positive in situ signals for era1 RNA are detectable 
in the embryos before hatching (Kawamura et al., 2002). Transcription of era1 
is not regulated by RA because RA synthesis inhibitor, DEAB, did not affect era1 
RNA level at the concentration (20 μM) (not shown) that completely inhibits the 
development of vessel and body-axis (Hayashida et al., 2004). 
To investigate the effect of overexpression of ERα on ahr1 expression, we 
introduced a series of increasing concentrations of a plasmid DNA expressing 
ERα (era1 plasmid) (Kawamura et al., 2002) into one- to four-cell stage embryos 
by the aid of electroporation, and analyzed transcript levels at 36 hpf from ahr1 
as well as genes encoding choriogenins H and L (Lee et al., 2002) as positive 
controls and β-actin gene as a negative control (Fig. 26B). ahr1 RNA became 
more abundant with increasing levels of era1 RNA expressed from the 
introduced plasmid. Transcriptions from the choriogenin genes were also 
activated, while β-actin RNA levels were constant regardless of era1 RNA levels. 
The ERα-induced transcriptional activation of ahr1 and the choriogenin H gene 
was inhibited by the presence of the anti-estrogen TAM (Fig. 26C). These results 
indicate that ERα activates transcription of ahr1 after binding to maternal 
estrogen present in fertilized eggs. 
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To investigate the physiological significance of ERα in the transcription of 
ahr1 and embryonic development, we first examined whether an antisense-era1 
RNA could knock down the activity of ERα that induces transcriptional activation 
of the choriogenin gene. We introduced into embryos a dose of era1 plasmid 
alone or simultaneously ten-fold dose of a plasmid DNA (antisense-era1 
plasmid) expressing antisense RNA from the entire era1 cDNA sequence, and 
analyzed transcript levels of choriogenin H as well as those of β-actin, era1, and 
antisense-era1 as controls at 36 hpf (Fig. 26D). The antisense RNA inhibited the 
ERα-induced activation of choriogenin H RNA but did not affect RNA levels of 
era1 or β-actin, indicating the specific knockdown of the ERα activity by the 
antisense-era1 RNA probably at a translational level. 
We then examined whether the knockdown of ERα could affect transcription 
of ahr1. We observed that transcript level from ahr1 was not altered by the 
treatment either with the antisense-era1 plasmid or low dose of DEAB, but 
significantly reduced exclusively in the embryos treated with the antisense-era1 
plasmid followed by incubation in the presence of DEAB (Fig. 26E). The reduced 
level of ahr1 RNA was restored to a control level by introduction of the same 
dose of era1 plasmid as that of the antisense-era1 plasmid (Fig. 26F). These 
results indicate that ERα is essential for transcription of ahr1 in cooperation with 
RA. 
We then explored whether the knockdown of ERα could affect vascular 
development (Fig. 26G). In the embryos into which antisense-era1 plasmid was 
introduced followed by incubation in the absence of DEAB, vascular damages 
were temporarily observed at 3 dpf in small but significant percentage (24%, 
n=140). These damages were mostly dysgenesis of one of the Cuvierian ducts 
that crawl on the yolk from both sides of the base of the pectoral fin (Iwamatsu, 
2004). The embryos with the vascular damage were almost normal in other 
aspects of the development including circulation, and regenerated a new 
Cuvierian duct with the blood clots remaining on the original location of the 
degenerated duct at 4 dpf (marked by arrow). However, in the presence of 
DEAB (2 μM), the antisense-treated embryos had more severe defects in the 
vascular development at 3 dpf (50%, n=46) and thereafter. They failed to form 
yolk veins including the Cuvierian ducts and the vitellocaudal vein (Iwamatsu, 
2004) with no circulation, and exhibited blood clots at the blood island (marked 
by arrowhead). era1 plasmid suppressed the antisense-era1-induced vascular 
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defects, demonstrating that ERα is essential for vascular development 
coordinately with RA.  
 
Maternal estrogen modulates RA metabolism through binding to ERα. 
Because ectopic E2 reduces in vivo level of RA by activating cyp26a1 and 
repressing raldh2, we investigated a physiological role of maternal estrogen in 
the regulation of RA metabolism by analyzing the effect of TAM on expressions 
of raldh2 and cyp26a1. We first examined whether RA controls raldh2. RA 
deficiency caused by DEAB activated raldh2 while ectopic RA inhibited it (Fig. 
27A), indicating a feedback control of raldh2. Next we investigated whether 
maternal estrogen is involved in the negative regulation. We observed that the 
RA-induced repression was cancelled by addition of TAM both in the 18- and 
36-hpf embryos (Fig. 27B, C). Furthermore, DEAB and TAM synergistically 
relieved raldh2 of its transcriptional burden (Fig. 27D). These results suggest 
that maternal estrogen is important for the feedback repression of raldh2 and 
exclude the possibility that the TAM-induced derepression of raldh2 occurs 
indirectly through fgf8, an activator for raldh2 that is concurrently regulated by 
RA and maternal estrogen but is unresponsive to DEAB (Fig. 22G). We also 
examined whether intrinsic excess of RA caused by inhibition of CYP26 
represses raldh2 coordinately with maternal estrogen. As expected, we 
observed that R115866 repressed raldh2 which was recovered by addition of 
TAM (Fig. 27E). To test direct role of RA, experiment was done after addition of 
CHX. We observed that excess RA repressed raldh2 in the presence of CHX 
(Fig. 27F), indicating a direct role of RA. We also observed that the RA-induced 
repression remained unchanged after co-treatment with TAM (Fig. 27F), 
suggesting that maternal estrogen acts indirectly or that CHX serves as a 
specific stabilizer for RA signaling. 
   Next we examined whether RA controls cyp26a1. Ectopic RA as well as 
R115866-induced accumulation of RA activated cyp26a1 judging from higher 
signal intensity and broad expression area, while RA deficiency caused by 
DEAB inhibited cyp26a1 (Fig. 28A), indicating a feedback control of cyp26a1. 
We also observed excess RA activated cyp26a1 in the presence of CHX, in this 
case, with increase in signal intensity not in expression area (Fig. 28B). These 
results indicate a direct role of RA and suggest that the broaden area of cyp26a1 
expression was due to reduced cell movement that was caused by RA inhibition 
of fgf8. We also observed that the RA-induced activation was cancelled by 
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co-treatment with TAM (Fig. 28C), indicating a role of maternal estrogen in the 
feedback control of cyp26a1.   
   We also investigated a physiological role of maternal estrogen in the 
regulation of RA metabolism by analyzing the effect of overproduction or 
knockdown of ERα on raldh2 expression. We anticipated that overproduction 
and knockdown of ERα would decrease and increase raldh2 expression, 
respectively. However, we observed that both activated raldh2 (Fig. 29A). 
Because overproduction of ERα causes phenotypic traits like RA deficiency 
(Figs. 7C, D), the increase in raldh2 expression by ERα-OP is considered due to 
derepression of raldh2 from negative control by RA. The increase in raldh2 
expression by ERα-KD is consistent with the conclusion that ERα controls raldh2 
negatively. We also examined the effect of ERα-KD on RA-induced repression of 
raldh2. Unlike our expectation that it restores the expression of raldh2, it caused 
a further decline in raldh2 expression (Fig. 29B). From this result, we speculated 
that ERα-KD caused an increase in RA level. To test this, we examined the 
effect of overproduction or knockdown of ERα on RA-inducible rarα expression, 
resulting in activation of rarα in both cases (Fig. 29C). The increase by ERα-OP 
is consistent with the conclusion that ERα activates rarα. The increase by 
ERα-KD is considered due to activation of rarα by an increase in RA level.                   
We also investigated the effect of overproduction or knockdown of ERα on 
cyp26a1 expression. We anticipated that overproduction and knockdown of ERα 
would increase and decrease cyp26a1 expression, respectively. As expected, 
ERα-OP considerably activated cyp26a1 judging from increase in intensity but 
not in area of cyp26a1 expression (Fig. 29D), suggesting that it causes RA 
deficiency. However, ERα-KD showed no significant effect (Fig. 29D). We then 
examined the effect of ERα-KD on RA-induced activation of cyp26a1. 
Expectedly, it impaired the activity of RA regarding both intensity and area of 
cyp26a1 expression (Fig. 29E), indicating that ERα activates cyp26a1 in 
coordination with RA. We speculate that ERα activates transcription of cyp26a1 
and controls expression area of cyp26a1 by repressing fgf8 coordinately with 
RA. 
   Our studies highlight a role of maternal estrogen/ERα in the regulatory 
mechanism for feedback control of RA level, which includes raldh2, cyp26a1, 
and fgf8. Elevated concentration of in vivo RA directs the expression of the 
regulatory genes toward lowering RA level in coordination with maternal 
estrogen through four routes: direct repression of raldh2, reduced activation of 
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raldh2 caused by repression of fgf8 that is a positive regulator of raldh2, direct 
activation of cyp26a1, and indirect activation of cyp26a1 by repressing fgf8 that 
is a negative regulator of cyp26a1. We observed that activation of ERα by either 
excess E2 or overproduction of ERα causes RA deficiency. On the contrary, we 
speculate that inactivation of ERα by either TAM or ERα-KD increases RA level. 
If our model was correct, treatment of CYP26-inactive embryos with TAM would 
further increase RA level. To test this, we investigated vascular damages and 
rarα expression after co-treating embryos with R115866 (CYP26 inhibitor) and 
TAM. As expected, we observed synergistic inhibition of the development in 
vasculature, head, and tail which are characteristic to excess RA (Fig. 30A). 
Expressions of rarα in the posterior hindbrain at 36 hpf (Fig. 30B) and in the 
prospective tail region at 18 hpf (Fig. 30C) were also synergistically activated by 
R115866 and TAM. Furthermore, we investigated whether TAM would increase 
vascular damages and rarα expression in the presence of 4-oxo-RA, an active 
retinoic acid that is generated in the metabolic pathway downstream from the 
reaction of CYP26a1 (Pijnappel et al., 1993; Topletz et al., 2015). We observed 
synergistic inhibition of vascular formation (Fig. 30D). We also observed that 
4-oxo-RA activated rarα expression at 18 hpf and that TAM further increased its 
expression (Fig. 30E). Collectively, these results suggest that TAM increases RA 
level and that maternal estrogen plays a critical role in the feedback control of in 
vivo level of RA.           
 
DISCUSSION 
Our data demonstrate the importance of maternal estrogen and its receptor ERα 
in the early embryonic development of medaka fish. Our findings reveal a 
functional cooperation between the two ubiquitous molecules, estrogen and RA, 
both in the feedback control of in vivo level of RA and in the transcriptional 
activation of RA-inducible genes. In our model (Fig. 31), activation of maternal 
estrogen/ERα leads to decreasing RA level and conversely upregulates 
RA-inducible gene expression. Thus, maternal estrogen/ERα acts as a buffer 
against developmental misregulation and environmental change in RA 
metabolism and signaling. Maternal estrogen/ERα may play a limited role in 
normal development but is vital in RA-deficient and -excess embryos. Indeed, 
we observed no effect of the antiestrogenic drug (TAM) in the normal 
development but clear effects in RA-deficient and -excess embryos. In a 
nutritional point of view, maternal estrogen may serve to moderate RA deficiency 
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that occurs from a shortage of maternally derived vitamin-A, a precursor of RA. 
Since RA plays fundamental roles in many aspects of animal development 
acting as a morphogen that forms a gradient of concentrations in developing 
embryos (Maden, 2002; Rhinn & Dollé, 2012), the synergistic activation of RA 
signaling by maternal estrogen may be important for spatial control of gene 
expression. Although molecular mechanisms for the cooperation between RAR 
and ERα are at present unknown in medaka, it is interesting to speculate a 
transcriptional control of target genes with binding sites for RAR and ERα at 
nearby or overlapping cis-regulatory elements. Hua et al. (2009) reported that 
binding sites for RAR and ERα are highly coincident throughout the human 
genome. They proposed a genome-wide crosstalk of RA and estrogen signaling 
to antagonistically regulate breast cancer-associated genes. The transcriptional 
linkage between RA and estrogen may be conserved in vertebrate. We also 
speculate that lower activity of RA signaling that activates Hox gene expression 
at 1 μM concentration in basal chordata, amphioxus (Branchiostoma floridae) 
and ascidian (Ciona intestinalis), which is 100-fold higher concentration than in 
vertebrate, may be in part due to lack of estrogen-responsive ER in their 
genomes (Koop et al., 2010; Nagatomo et al., 2003; Paris et al., 2008). Little has 
been learned about the developmental roles of ER genes in lower vertebrates 
(Celeghin et al., 2011; Froehlicher et al., 2009; Gamba et al., 2010). In order to 
characterize the physiological roles of ER genes, it may be necessary to explore 
synergistic conditions or synthetic lethal relationship between er mutation and 
RA-related one. 
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Figure 1. Hyperactivation of ERα causes loss of CCV.  
(A) Staged embryos were treated with E2 (4 mg/l) and examined at 3 dpf for 
vascular damages. % Embryos with vascular damages or curved tail (inset; 
blood aggregates marked by an arrow) were shown. (B) Wild-type embryos and 
transgenic ones overproducing ERα were treated with E2 at the indicated 
concentration and examined for vegfr1+ angioblasts at 48 hpf. Arrows indicate 
CCV. (C) Wild-type embryos were treated with E2 (4 mg/l) and examined for 
vegfr1+ angioblasts at PBA (bracket) at 36 and 48 hpf. Open arrowhead 
indicates otic vesicle.  
 
Figure 2. Excess RA causes loss of CCV.  
(A) Staged embryos were treated with RA (9 nM) and examined at 48 hpf for 
vegfr1+ angioblasts. % Embryos without CCV were shown. (B) Embryos were 
treated with R115866 (a specific inhibitor of CYP26) (10 μM) and DEAB (a RA 
synthesis inhibitor) (1 μM) either alone or together as indicated, and 
photographed at 3 dpf. % Embryos with vascular damages were shown.  
* p<0.002; ** p<0.00001. 
 
Figure 3. MAP kinase pathway inhibitor (PD98059) causes loss of CCV.  
(A) Embryos were treated with PD98059 (5 μM) and examined at 36 hpf for 
expression of sprouty4. (B) Embryos were treated with PD98059 at the indicated 
concentration and examined at 3 dpf for vascular damages. % Embryos with 
vascular damages were shown. Embryos treated with the drug (20 μM) were 
also examined for vegfr1+ angioblasts at 48 hpf. (C) 5-dpf embryos with curved 
tail treated with the drug (20 μM). (D) Staged embryos were treated with the drug 
(20 μM) and examined for vascular damages at 3 dpf and for vegfr1+ angioblasts 
at 48 hpf. * p<0.0001.     
 
Figure 4. Cyclopamine causes loss of CCV. 
(A, B) Embryos were treated with cyclopamine at the indicated concentration 
and examined for vascular damages at 3 dpf (A) and for vegfr1+ angioblasts at 
48 hpf (B). (C) Embryos were treated with the drug (10 mg/l) and photographed 
at the indicated time. (D) Embryos were treated with the drug (25 mg/l) and 
examined for vegfr1+ angioblasts at 48 hpf. * p<0.0001.    
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Figure 5. Effects on myoD expression of DEAB, RA, PD98059, cyclopamine, 
and E2. myoD expression was examined at 44 hpf after treating embryos with 
the following drugs: (A) DEAB (10 μM), or RA (10 nM), (B) PD98059 (20 μM) or 
cyclopamine (40 mg/l), (C) E2 (4 mg/l), and (D) E2 (4 mg/l), DEAB (10 μM), or 
E2 (4 mg/l) plus DEAB (10 μM).   
 
Figure 6. Effects of E2, PD98059, and DEAB on expressions of shh and no 
tail. (A, B) Embryos were treated with E2 (4 mg/l) and examined for expression 
of shh (A) or no tail (B) at the indicated time. (C) Embryos were treated with 
PD98059 (20 μM) or DEAB (50 μM) and examined for shh expression at 36 hpf. 
 
Figure 7. Synergistic effects. 
(A) Embryos were treated with E2 and DEAB at the indicated concentration and 
examined for vascular damages at 3 dpf. (B) Staged embryos were treated with 
E2 and DEAB at the indicated concentration and examined for vascular 
damages at 3 dpf. (C) Wild-type and ERα-overproducing transgenic embryos 
were treated with E2 and DEAB at the indicated concentration and examined for 
vascular damages at 3 dpf. (D) Wild-type embryos with the ERα-overproducing 
plasmid DNA (pOL22) introduced by electroporation were treated with DEAB 
and examined for vascular damages at 3 dpf. (E, F) Embryos were treated with 
PD98059 and DEAB at the indicated concentration and examined for vascular 
damages at 3 dpf (E) and for vegfr1+ angioblasts at 48 hpf (F). (G) Embryos 
were treated with DEAB (2 μM) at 10 hpf, added with PD98059 (5 μM) at the 
indicated time, and examined for vascular damages at 3 dpf. (H) Embryos were 
treated with PD98059 and E2 at the indicated concentration and examined for 
vascular damages at 3 dpf and for curved tails at 5 dpf. (I) Embryos were treated 
with PD98059 and RA at the indicated concentration and examined for vascular 
damages at 3 dpf. (J) Embryos were treated with PD98059 and RA at the 
indicated concentration and examined for vegfr1+ angioblasts at 48 hpf. (K) 
Embryos were treated with E2 and RA at the indicated concentration and 
examined for vascular damages at 3 dpf. (L) Staged embryos were treated with 
E2 and RA at the indicated concentration and examined for vascular damages at 
3 dpf. * p<0.05; ** p<0.01; *** p<0.001. 
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Figure 8. Effect of E2 on hindbrain formation.  
(A) Embryos were treated with E2 and DEAB at the indicated concentration and 
examined for rhombomere formation at 58 hpf. (B) Synergistic effect of E2 and 
DEAB on rhombomere formation. Arrows indicate boundary between 
rhombomeres. OV, otic vesicle.    
 
Figure 9. Effect of E2 on RA-inducible gene expression.  
(A) Embryos were treated with Ro41-5253 (5 μM), 17β-E2 (4 mg/l), and 17α-E2 
(4 mg/l) and examined for expression of the genes indicated at 36 hpf. (B) 
Embryos were treated with E2 and/or DEAB at 10 or 20 hpf and examined for 
expression of rarα and hoxa3a at 36 hpf. Open arrowhead indicates no 
expression of hoxa3a at r-7 to r-8. (C) Staged embryos were treated with E2 and 
examined for rarα expression at 36 hpf. Embryos of 10, 16, and 19 hpf are at 
developmental stage of late blastula, mid-gastrula, and pre-late gastrula, 
respectively. (D) Embryos were treated with E2 at the indicated concentration 
and examined for rarα expression (in circle) at 18 hpf. * p<0.01. 
 
Figure 10. Effect of E2 on raldh2 and cyp26a1 expression.   
(A) Embryos were treated with E2 at 10 hpf, added with cycloheximide at 18 hpf, 
fixed at 23 hpf, and examined for raldh2 expression. (B) Embryos were treated 
with E2 at 18 hpf 1 h after addition of cycloheximide, and examined for raldh2 
expression. (C) Embryos were treated with E2 as indicated and examined for 
cyp26a1 expression. (D) Embryos were treated with E2 after addition of 
cycloheximide as indicated, and examined for cyp26a1 expression.     
 
Figure 11. Effect of PD98059 on RA-controlled gene expression.  
(A) Embryos were treated with PD98059 at the indicated concentration and 
examined for expression of the genes indicated at 36 hpf. (B) Embryos were 
treated with PD98059 and/or DEAB and examined for rarα expression at 36 hpf. 
(C) Staged embryos were treated with PD98059 (5 μM) and DEAB (2 μM) and 
examined for rarα expression at 36 hpf. % Embryos with no rarα expression are 
shown. (D) Embryos were treated with PD98059 and examined for rarα 
expression at 18 hpf. * p<0.01; ** p<0.001. 
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Figure 12. Effect of PD98059 on raldh2 and cyp26a1 expression.   
(A) Embryos were treated with PD98059 at 10 hpf, added with cycloheximide at 
18 hpf, fixed at 23 hpf, and examined for raldh2 expression. (B, C) Embryos 
were treated with PD98059 at 10 hpf, added with cycloheximide at 18 hpf (B) or 
24 hpf (C), fixed 5 h later, and examined for cyp26a1 expression. * p<0.001. 
 
Figure 13. Effect of PD98059 on ahr1 expression.  
(A) Embryos were treated with PD98059 and/or DEAB and examined for ahr1 
expression at 48 hpf. (B) Embryos were treated with PD98059 and examined for 
ahr1 expression at 48 hpf. Closed arrowhead, ahr1 expression at PBA; open 
arrowhead, otic vesicle; * p<0.005. 
 
Figure 14. Effect of E2 on FGF signaling.  
(A) Expression of fgf3 and fgf8 during somite stage. (B) Effect of E2 on fgf3 and 
fgf8 expression. (C) Effect of E2 on sprouty4 expression. (D) Embryos were 
treated with increasing concentrations of E2 as indicated and examined for 
sprouty4 expression at 36 hpf. MHB, midbrain-hindbrain boundary; TB, tail bud; 
TEL, telencephalone.   
 
Figure 15. Effect of ERα overproduction on fgf8 and myoD expression.  
Expression of fgf8 and myoD was examined at 36 and 44 hpf, respectively, in 
the embryos injected with plasmid DNA (pOL22) overproducing ERα.     
 
Figure 16. Effect of RA on fgf8 and sprouty4 expression.  
(A) Staged embryos were treated with RA (9 nM) and examined for fgf8 and 
sprouty4 expression at 36 hpf. (B) % Embryos with no sprouty4 expression at 
MHB or adaxial mesoderm (AM) and relative length of sprouty4 signal at tail bud 
(TB) are shown. % Embryos with vascular damages from Hayashida et al. 
(2004). Arrows indicate that embryos were affected before the time marked.  
* p<0.001.     
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Figure 17. Effect of RA on ahr1 expression.  
(A) Staged embryos were treated with RA (10 nM) and examined for ahr1 
expression at 48 hpf. (B) Average length from top of head to otic vesicle marked 
by double arrowhead in (A). Open arrowhead, otic vesicle; closed arrowhead, 
ahr1 expression at PBA; Grey arrowhead, ahr1 expression at otic vesicle.  
* p<0.0001.  
 
Figure 18. Effect of fgf8 knockdown on CCV formation and RA metabolism 
and signaling. (A) Embryos were injected with control-MO or fgf8-MO and 
examined for the expression as follows: ahr1 (48 hpf), cyp26a1 (18 hpf), raldh2 
(18 hpf), rarα (18 or 36 hpf), sprouty4 (36 hpf), and vegfr1 (48 hpf). (B) Embryos 
were injected with control-MO or fgf8-MO, incubated in the presence or absence 
of DEAB, and examined for rarα expression at 36 hpf. Arrowhead, PBA; arrow, 
tail tip.   
 
Figure 19. Effect of antiestrogen on hindbrain formation.  
(A) 54-hpf DAPI-stained embryos treated with E2 (2 mg/l), DEAB (10 μM), RA 
(10 nM), RA (10 nM) + TAM (4 mg/l), or RA (10 nM) + TAM (4 mg/l) + E2 (2 mg/l). 
Number, rhombomere; arrow, otic vesicle. (B) Embryos were treated with RA (10 
nM) or RA (10 nM) + TAM (4 mg/l), and examined for krox20 expression at 36 
hpf. Arrows indicate RA-induced anterior shift of r-3 and r-5 and its recovery by 
TAM. (C) Embryos were treated as indicated and examined for expressions of 
rarα and hoxa3a at 36 hpf. (D) Staged embryos were treated as indicated and 
examined for rarα expression at 36 hpf. (E) Relative intensity and area of rarα 
expression in (D). Broken line indicates control level. (F) Relative length from top 
of head to rarα signal (bracket) in (D). * p<0.001; ** p<0.0001.          
 
Figure 20. Effect of antiestrogen on rarα expression during gastrula stage. 
(A) Staged embryos were analyzed for rarα expression by in situ hybridization 
using anti-sense and sense probes. (B) Embryos were treated with RA (10 nM) 
or RA (10 nM) + TAM (4 mg/l) as indicated and examined for rarα expression. 
(C) Embryos were first treated with cycloheximide, then with RA (10 nM) or RA 
(10 nM) + TAM (4 mg/l) as indicated, and examined for rarα expression.  
 * p<0.005; ** p<0.001; n.s., not significant.    
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Figure 21. Effect of antiestrogen on ahr1 expression.  
Embryos were treated with RA (10 nM), RA (10 nM) + TAM (0.5 mg/l), or RA (10 
nM) + TAM (0.5 mg/l) + E2 (2 mg/l) as indicated, and examined for ahr1 
expression. Open arrowhead, otic vesicle; closed arrowhead, ahr1 expression at 
PBA. Average length from top of head to otic vesicle marked by double 
arrowhead is also shown. * p<0.05; ** p<0.0001.  
 
Figure 22. Effect of antiestrogen, ERα-KD, and RA on FGF signaling.  
(A) Embryos were treated with RA (9 nM) and/or TAM (4 mg/l) as indicated and 
examined for sprouty4 expression at 36 hpf. Bracket indicates sprouty4 
expression at adaxial mesoderm. (B) Embryos were treated with RA (9 nM) at 10 
hpf, added with TAM (4 mg/l) at the indicated time, and examined for fgf8 
expression at 36 hpf. (C, D) Embryos were treated as in (A) and examined for 
expressions of fgf8 (C) and sprouty4 (D) at the indicated time. Arrowhead 
indicates split of the signal caused by gastrulation delay. (E) fgf8 expression in 
19-hpf embryos injected with plasmid DNA expressing anti-sense ERα RNA. (F) 
Embryos were treated with cycloheximide at 16 hpf, added with RA (9 nM) at 17 
hpf, fixed at 22 hpf, and examined for fgf8 expression. (G) Embryos were treated 
with DEAB (50 or 10 μM), and examined for fgf8 expression at 19 or 36 hpf, 
respectively. (H) fgf8 expression in 19-hpf embryos treated with R115866 (10 
μM).         
 
Figure 23. Effect of antiestrogen on vascular formation.  
(A, B) Embryos were treated as indicated and examined for vascular 
damages. % Embryos with vascular damages are shown. (A) Suppression of the 
RA-induced vascular damages by co-treatment with TAM, and its cancellation by 
further addition of E2. (B) TAM-induced recovery from the synergistic inhibition 
of vascular formation by RA and E2. * p<0.01. (C) Embryos were treated with RA 
(9 nM) at 10 hpf, added with TAM at the indicated time, and examined for 
vascular damages and body-axis malformation. Values for embryos treated with 
RA alone were marked by arrows (closed, vascular damages; open, body-axis 
malformation). 3-dpf embryos are also shown for control and the treatment with 
RA alone or with RA together with addition of TAM at 10 or 16 hpf.  
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Figure 24. Synergistic inhibition of vascular formation by TAM and DEAB. 
(A, B, C, D) Embryos were treated as indicated and examined for vascular 
damages (A, C, D) and vegfr1+ CCV (B). (A) Synergistic inhibition of vascular 
formation. (B) Synergistic inhibition of CCV formation. (C) Rescue by addition of 
RA. (D) Rescue by addition of E2. (E) Staged embryos were treated with DEAB 
and TAM as indicated (gray diamond, circle, open square). Embryos were also 
treated with DEAB at 10 hpf and added with TAM at the indicated time (closed 
square). % Embryos with vascular damages are shown. (F) Staged embryos 
were treated with DEAB and TAM as indicated, and examined for vegfr1+ CCV.  
* p<0.05; ** p<0.005. 
 
Figure 25. Control of ahr1 transcript levels by RA and maternal estrogen.  
(A, B, C, D) Embryos were treated as indicated and examined for ahr1 transcript 
levels at 36 hpf by RT-PCR. rRNA is used as a control for the total RNA content 
used in RT-PCR. (A) Synergistic activation by RA and E2. (B) Suppression by 
TAM of RA-induced activation, and its cancellation by E2. (C) Synergistic 
inhibition by DEAB and TAM. (D) Rescue by RA from the synergistic inhibition by 
DEAB and TAM. (E, F) Embryos were treated as indicated and examined by in 
situ hybridization for ahr1 expression at 48 hpf (E) and for rarα expression at 36 
hpf (F). Closed arrowhead, ahr1 expression at PBA; open arrowhead, no 
expression.      
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Figure 26. ERα is essential for ahr1 expression and vascular formation. 
(A) Transcript levels from era1 (ERα) and β-actin genes at the indicated 
developmental period. (B) Activation of ahr1 and genes for choriogenins (chg) H 
and L at 36 hpf after electroporation with increasing doses of the era1-plasmid 
(pOL22). (C) Inhibition of the era1-induced overexpression of ahr1 and chg-H by 
the treatment with TAM. (D) Inhibition of the era1-induced overexpression of 
chg-H by the antisense-era1-plasmid (pOL23). Transcript levels of chg-H were 
normalized by β-actin RNA. (E) Inhibition of ahr1 expression in the embryos 
treated with the antisense-era1-plasmid followed by incubation in the presence 
of DEAB. (F) Restoration from the antisense-era1-induced inhibition of ahr1 by 
the era1-plasmid. (G) Embryos (upper, 4 dpf; lower, 3 dpf) treated with or without 
the antisense-era1-plasmid followed by incubation in the presence or absence of 
DEAB. Vascular damages represented by blood clots on the yolk (arrow) and at 
the blood island (arrowhead). % Embryos with vascular damages are shown. 
GFP-expressing embryos (approximately 20% of the treated embryos) were 
collected at 36 hpf for extraction of total RNA and at 2 dpf for observation of 
vascular damages at 3 dpf in (E) to (G). DNA concentrations (μg/μl) of the 
plasmids in 10 x Yamamoto’s solution were as follows: 0.01, 0.05, 0.1, and 0.5 
for pOL22 in (B); 0.5 for pOL22 in (C); 0.05 for pOL22 and 0.5 for pOL23 in (D); 
0.5 for pOL21 and pOL23 in (E); 0.5 for pOL21, pOL22, and pOL23 in (F, G).  
* p <0.01, ** p<0.05. 
 
Figure 27. Control of raldh2 expression by RA and maternal estrogen.  
Embryos were treated with DEAB (10 μM), RA (10 nM), TAM (4 mg/l), and 
R115866 (1.0 μM) as indicated and examined for raldh2 expression. (A) 
Activation by DEAB and inhibition by RA. (B, C) Rescue by TAM from the 
RA-induced inhibition at 18 hpf (B) and 36 hpf (C). (D) Synergistic activation by 
co-treatment with DEAB and TAM. (E) Rescue by TAM from the inhibition by 
R115866-induced RA excess. (F) Inhibition by RA but no effect of TAM after 
pretreatment with cycloheximide. * p<0.01. 
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Figure 28. Control of cyp26a1 expression by RA and maternal estrogen.        
Embryos were treated with RA (10 nM), R115866 (1.0 μM), DEAB (10 μM), and 
TAM (4 mg/l) as indicated and examined for cyp26a1 expression. (A) Activation 
by RA or R115866, and inhibition by DEAB. (B) Direct activation by RA. (C) 
Cancellation by TAM of the RA-induced activation.  
 
Figure 29. Effects of overproduction and knockdown of ERα on 
expressions of raldh2, rarα, and cyp26a1. Embryos were injected with 
plasmid DNA (pOL21 for control; pOL22 for overproduction of ERα; and pOL23 
for knockdown of ERα), added with cycloheximide at 18 hpf, and fixed at 23 hpf. 
RA was added at 10 hpf. (A) Activation of raldh2 by overproduction or 
knockdown of ERα. (B) RA-induced repression of raldh2 and its additional 
reduction by knockdown of ERα. (C) Activation of rarα by overproduction or 
knockdown of ERα. (D) Activation of cyp26a1 by overproduction of ERα. No 
effect of knockdown of ERα on cyp26a1 expression. (E) RA-induced activation 
of cyp26a1 and its reduction by knockdown of ERα. 
 
Figure 30. TAM advances RA-excess phenotypes.  
(A) Synergistic inhibition of vascular formation by TAM and R115866. 3-dpf 
embryos are also shown. * p<0.001; ** p<0.0002. (B) Synergistic activation of 
rarα expression at 36 hpf by TAM and R115866. * p<0.0003; ** p<0.0001. (C) 
Synergistic activation of rarα expression at 18 hpf by TAM and R115866. * 
p<0.05. (D) Synergistic inhibition of vascular formation by TAM and 4-oxo-RA. * 
p<0.01. (E) Synergistic activation of rarα expression at 18 hpf by TAM and 
4-oxo-RA. * p=0.00001; ** p<0.00001. 
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Figure 31. A model for how maternal estrogen/ERα controls RA 
metabolism and signaling. RA is produced by Raldh2 from maternally 
deposited retinal. RA is converted to 4-OH-RA by Cyp26a1 and led to the 
degradative pathway through an active retinoid, 4-oxo-RA. RA level is controlled 
by the feedback mechanisms. RA directly represses raldh2 expression and 
activates cyp26a1 expression in order to lower RA level. RA is also involved in 
the feedback regulation indirectly through inhibition of fgf8 that is both an 
activator for raldh2 and a negative regulator against cyp26a1. RA is required for 
expressions of rarα and ahr1 that are essential for the formation of CCV, 
prospective Cuvierian ducts. RA is also required for A-P patterning of hindbrain 
(not shown). Maternal estrogen/ERα (oval with a pen point) acts cooperatively 
with RA. Inhibition of its function with an anti-estrogen, TAM, or knockdown of 
ERα abolishes the feedback regulation of RA level, resulting in excess RA. On 
the contrary, excess estrogen or overproduction of ERα stimulates degradation 
of RA. Maternal estrogen/ERα, on the other hand, activates RA signaling and is 
essential for vascular and hindbrain formation. Fgf8 is required for RA synthesis 
by activating raldh2 and, independently of it, for CCV formation. Regional 
expression of cyp26a1 in the anterior brain is regulated in part through fgf8 
function in the cell migration during epiboly/gastrulation. Lower left, expression 
patterns of cyp26a1, fgf8, and raldh2 in the 50% epiboly, in which RA level is 
controlled by the regulatory circuit shown above. Lower right, expression 
patterns of ahr1 (PBA), fgf8 (MHB and adaxial mesoderm), krox20 (r-3 and r-5), 
rarα (r-7 to r-8), shh (midline), and vegfr1 (precursor of CCV), and the 
expression of VEGF, which is proposed to be under control of ahr1 and is 
required for accumulation of vegfr1+ cells at PBA (Sada et al., 2019).               
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Figure 1. Hyperactivation of ERα causes loss of CCV.  
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Figure 2. Excess RA causes loss of CCV. 
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Figure 3. MAP kinase pathway inhibitor (PD98059) causes loss of CCV.  
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Figure 4. Cyclopamine causes loss of CCV. 
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Figure 5. Effects on myoD expression of DEAB, RA, PD98059, cyclopamine, 
and E2. 
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Figure 6. Effects of E2, PD98059, and DEAB on expressions of shh and no 
tail. 
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Figure 7. Synergistic effects. 
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Figure 7. (continued) 
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Figure 7. (continued) 
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Figure 8. Effect of E2 on hindbrain formation. 
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Figure 9. Effect of E2 on RA-inducible gene expression. 
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Figure 9. (continued) 
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Figure 10. Effect of E2 on raldh2 and cyp26a1 expression. 
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Figure 11. Effect of PD98059 on RA-controlled gene expression.  
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Figure 11. (continued) 
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Figure 12. Effect of PD98059 on raldh2 and cyp26a1 expression. 
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Figure 13. Effect of PD98059 on ahr1 expression.  
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Figure 14. Effect of E2 on FGF signaling.  
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Figure 14. (continued) 
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Figure 15. Effect of ERα overproduction on fgf8 and myoD expression.  
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Figure 16. Effect of RA on fgf8 and sprouty4 expression.  
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Figure 17. Effect of RA on ahr1 expression.  
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Figure 18. Effect of fgf8 knockdown on CCV formation and RA metabolism 
and signaling. 
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Figure 19. Effect of antiestrogen on hindbrain formation.  
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Figure 19. (continued) 
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Figure 19. (continued) 
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Figure 20. Effect of antiestrogen on rarα expression during gastrula stage. 
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Figure 20. (continued) 
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Figure 21. Effect of antiestrogen on ahr1 expression.  
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Figure 22. Effect of antiestrogen, ERα-KD, and RA on FGF signaling.  
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Figure 22. (continued) 
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Figure 23. Effect of antiestrogen on vascular formation.  
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Figure 24. Synergistic inhibition of vascular formation by TAM and DEAB. 
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Figure 25. Control of ahr1 transcript levels by RA and maternal estrogen.  
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Figure 26. ERα is essential for ahr1 expression and vascular formation. 
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Figure 26. (continued) 
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Figure 27. Control of raldh2 expression by RA and maternal estrogen.  
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Figure 27. (continued) 
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Figure 27. (continued) 
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Figure 28. Control of cyp26a1 expression by RA and maternal estrogen.   
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Figure 29. Effects of overproduction and knockdown of ERα on 
expressions of raldh2, rarα, and cyp26a1. 
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Figure 30. TAM advances RA-excess phenotypes.  
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Figure 30. (continued) 
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Figure 31. A model for how maternal estrogen/ERα controls RA 
metabolism and signaling. 
 
 
 
 
 
 
 
